Background
The COVID-19 pandemic, caused by SARS-CoV-2, is characterized by a diversity of clinical manifestations, including exacerbated inflammatory states accompanied with tissue and organ destruction beyond direct viral cytopathic effects. From the outset of the pandemic, it became clear that, while men and women present a similar prevalence of infection [
1,
2], a higher risk of severe disease and death is significantly associated with male sex [
2,
3], similar to the other pathogenic coronaviruses, SARS-CoV and MERS-CoV, and other viral respiratory infections [
4,
5]. Multiple factors have been considered to explain the sex disparity observed in the development of severe COVID-19, including differential biological and pathophysiological impacts of age and comorbidities such as cardiovascular disease, high blood pressure, chronic obstructive pulmonary disease (COPD), diabetes, obesity, or active cancer [
6]. Gender differences in disease severity are also observed in racial and ethnic minority groups, disproportionately affected by COVID-19 [
6].
The underlying mechanisms that may account for the differences between men and women in the development of severe COVID-19 are not completely understood. As the main cellular receptor for SARS-CoV-2, ACE2, and the major viral fusogenic membrane-associated protease, TMPRSS2, are under transcriptional regulation by androgens [
7], it had been predicted that men would present a higher propensity of infection by SARS-CoV-2 and to develop more severe disease than women [
7,
8]. However, men and women show comparable risks of infection [
1,
2] and observational studies of male COVID-19 patients under androgen-deprivation therapy have yielded contrasting results with regard to risk of developing severe COVID-19 (ref. [
9,
10]). Contrariwise, there is growing evidence that severe COVID-19 in male patients is accompanied with diminished levels of circulating testosterone [
11‐
13], suggesting a critical role for androgens [
11,
14] and androgen receptor, AR [
15], in preventing the innate and/or adaptive immune dysfunctions that lead to the development of severe forms of the disease [
16‐
18]. A role on coagulation for testosterone has also been suggested as a factor to consider in COVID-19 pathogenesis [
19,
20].
The sexual dimorphism of immune responses to pathogens has been long recognised [
21], pointing to women having stronger antiviral mechanisms, stronger T regulatory cells, higher numbers of group 2 innate lymphoid cells (ILC2), and superior immune-mediated tissue repair capacities as compared to men [
22,
23]. In addition, sex hormones may differentially impact the frequency and severity of many autoimmune and inflammatory diseases, generally more prevalent in women than men [
24,
25]. It should be noted that sex hormones may exert apparently contrasting effects. For example, an immunosuppressive role for testosterone was observed in response to influenza vaccination [
26], while testosterone supplementation following influenza infection in aged male mice, which caused decreased serum testosterone levels, reduced mortality [
27].
In order to better understand the relationship between testosterone status and disease severity, we have analyzed serum biomarkers, including testosterone, and immune cell subpopulations in COVID-19 patients in association with disease outcome. We have found that the trajectories of serum testosterone levels are highly accurate predictors of survival in male COVID-19 patients. Furthermore, we establish that male COVID-19 patients with a fatal outcome display a late coordinated depletion of circulating subsets of differentiated CD4+ T lymphocytes and monocytes, mirrored by a relative enrichment of undifferentiated CD4+ T cells and monocytes.
Discussion
Numerous studies have identified prognostic markers able to discern severe COVID-19 patients, including older age, male sex, co-morbidities such as obesity, diabetes, or cardiovascular disease, elevated circulating markers of inflammation, lymphopenia, neutrophilila [
2,
12,
17,
32‐
34,
36], or the presence of autoantibodies to class-I interferons [
37]. Nomograms or scores that combine several independent parameters have been proposed as predictors of COVID-19 outcome [
2,
12,
32]. However, relatively few studies have addressed sex differences in predictive markers of disease outcome [
2,
12,
32,
38‐
40]. Interestingly, inflammation markers, but not co-morbidities, BMI, or age, have been found to be associated with outcome differences between male and female COVID-19 patients [
40].
Our comparative analysis of biochemical and hematological parameters has revealed that both sexes share markers with significant predictive power of disease outcome, including IL-6, LDH, D-dimer, lymphopenia, and neutrophilia. Nevertheless, the levels of these markers, and the strength of their predictive power, are consistently higher in male patients as compared to female patients. This becomes more evident when evaluating predictive markers of lethal COVID-19, which yields IL-6 and lymphocyte (percentage of total WBC) as the only two significantly predictive markers shared in both male and female patients. Other significant markers predictive of lethal COVID-19 in male but not female patients are LDH levels, neutrophilia, and absolute lymphocyte counts, in addition to testosterone levels, which are exclusively masculine in our patient cohorts. Furthermore, we found significant and direct correlations between testosterone levels, lymphocytes, and neutrophils, suggesting a role for testosterone in aberrant immune responses in deceased patients.
These observations suggest that male COVID-19 patients with severe and lethal disease suffer from more deleterious underlying pathogenic and inflammatory processes than female patients with comparable clinical severity [
2], a situation also observed in other respiratory viral infections [
4,
5]. Our baseline analysis reveals that critically low serum testosterone levels in male patients are a risk factor for severe COVID-19, along with other factors predictive of severity that are in line with prior evidence [
32,
34]. We have also found that male COVID-19 patients with a higher risk of progression to a severe-critical disease present higher levels of inflammatory markers (serum IL-6, blood neutrophil counts) and tissue damage (LDH), and more marked lymphopenia [
2], as compared to age-matched female patients.
Interestingly, markers of inflammation (IL-6, CRP) or tissue damage (LDH), with good outcome predictive power in admission sample determinations, lost their predictive power in longitudinal analyses in male patients, collected up to the time of discharge or death. In contrast, testosterone levels, whose determinations on admission provided a relatively modest outcome predictive power, corroborating other studies [
11,
13], gained remarkable levels of significance when analyzed longitudinally. The AUC values of ROC curves in logistic regression analyses (mild-moderate vs. severe: 0.9281, 95% CI 0.7216 to 0.9252,
p < 0.0001; severe survivor vs. deceased: 0.9205, 95% CI 0.8664 to 0.9747,
p < 0.0001) indicate that serum testosterone trajectories in longitudinal determinations constitute, to the best of our knowledge, the most accurate independent predictors of disease outcome in male COVID-19 patients described thus far. Furthermore, longitudinal trajectories of lymphocyte and neutrophil counts also yield highly significant predictions of disease outcome.
Other biochemical parameters indicative of pathological inflammatory or pro-coagulant states, such as elevated IL-6, CRP or D-dimer levels, eventually return to near-physiological levels in both survivors and patients with fatal outcomes. This has been observed in other studies [
40,
41] and suggests that the normalization of these factors is insufficient, per se, to abate the pathological hyperinflammation and hypercoagulation accompanying severe COVID-19 with a fatal outcome, which might require the concomitant alleviation of lymphopenia and neutrophilia. On the other hand, although different stimuli and conditions such as mechanical ventilation, muscle immobilization, severe sepsis, and multiple organ dysfunction as well as neuro/myotoxic agents may contribute to a critical status among patients admitted to ICU [
42], all severe patients in our study, with either survivor or deceased outcomes, were under comparable pharmacological and physical management (Additional file
1: Tables ST1 and ST2), and thus, these factors are unlikely to contribute to the differential outcomes in this study.
We have found that testosterone trajectories are not paralleled by changes in circulating LH or androstenedione trajectories expected in the presence of functioning physiological feedback loops. This could be explained by an inhibition of the LH-androstenedione axis, which has been associated with non-specific critical illness [
43] and the deleterious action on the hypophysis of inflammatory cytokines [
44]. A second possible mechanism may involve infection and damage by SARS-CoV-2 of ACE2-expressing testicular cells, mainly Leydig cells [
45,
46]. In the first scenario, acute declines in LH and adrostenedione levels would be expected, while in the latter scenario, they would be either unaffected or increased for LH due to a negative feedback loop with testosterone [
43]. However, we observed that LH levels showed a slight decline in deceased patients, while androstenedione levels were increased. It should be noted that circulating androstenedione is produced mostly by adrenal glands [
47] and its synthesis might be affected by the corticosteroids used to treat these patients (Additional file: Table
ST1B), which may block the endogenous production of cortisol, corticosterone, and aldosterone [
47]. Therefore, a likely mechanism to explain the failure of patients with fatal outcomes to recover their physiological levels of testosterone, combined with normal androstenedione levels and a lack of rise in LH, suggests a malfunction of the testosterone-LH feedback loop. As such, an irreversible damage of Leydig cells [
48] in patients with fatal outcomes could explain these observations, while a resolution of viral infection would explain the recovery of a normal production of testosterone in survivors.
Another relevant factor associated with late-onset hypogonadism [
49], as well as with an irreversible failure to reinstate testosterone production after critical situations that may compromise the LH-androstenedione axis, is old age [
50], which has been linked to senescent dysfunction of Leydig cells [
51]. The fact that a majority of non-survivor patients in our study who failed to reinstate testosterone levels are older than 60 years of age would be consistent with the senescence hypothesis. However, our cohort has more patients older than 60 who reinstated their testosterone levels and survived severe COVID-19. Therefore, either Leydig cell senescence only affects a small subset of older patients or other mechanisms may be invoked to explain failure to restore testosterone production.
Conversely, these observations also suggest that while the reinstatement of physiological testosterone levels may be mechanistically linked to a return to lymphocyte and neutrophil homeostasis, it may not be required for the relative normalization of other inflammatory pathways, arguably driven by an unmitigated production of IL-6 and other pro-inflammatory cytokines triggered by acute viral infection [
52]. Our observations suggest that sufficient and timely resolution of pathogenic hyperinflammation to prevent a lethal outcome may require the additional return to homeostasis of innate and/or adaptive immune cell dynamics and function, possibly assisted in male patients by the reinstatement of testosterone production.
There is now a wealth of studies describing the dynamics of immune responses to acute and subacute infection with SARS-CoV-2, including multiparameter and functional analyses of circulating and tissue-associated innate and adaptive immune subpopulations [
53,
54]. Some of these studies have addressed sex differences in such responses [
11,
14]. Our analysis in male patients indicates an association of specific immune subpopulations with COVID-19 outcome and a shift of such associations from early (Sample 1) to late (Sample 2) time-points in the course of the disease. For example, the relative representation of differentiated (CD8
+ TEMRA, CD4
+ TEMRA) and activated (HLA-DR
+ on CD4
+ and on CD8
+) T cell subpopulations and differentiating B cells modestly correlated with all outcomes except mild disease in Sample 1. This indicates an ongoing early immune response of similar nature and magnitude, regardless of final outcome, as reported by others [
53]. In this phase, non-classical monocytes are more prevalent than classical monocytes in patients with a moderate outcome, while patients with severe survivor and severe deceased outcomes show a predominance of more inflammatory [
55] classical monocytes, in support of a more inflammatory state of these patients, as also evidenced by the clinical biochemical and hematological parameters discussed above.
However, later in the course of disease (Sample 2), a remarkable shift takes place, in particular with regard to correlations with severe survivor as compared to severe deceased patients. As such, while patients with severe survivor outcomes show positive correlations with differentiated (CD4
+ TEMRA, CD8
+ TEMRA), activated (HLA-DR
+ on CD4
+ and on CD8
+), and memory (CD4
+ central memory, CD8
+ central memory) T cell subpopulations, patients with eventual fatal outcomes evidence a depletion of these subpopulations, along with an accumulation of undifferentiated T helper cells (recent thymic emigrant CD4
+ and naïve CD4
+). This late shift also affects innate immune populations, as severe survivor patients correlate with non-classical monocytes over classical monocytes, while the reverse is the case for severe deceased patients. Similar observations have been made by others in studies correlating innate [
53] and adaptive [
17] immune cell subpopulations to COVID-19 outcome.
Importantly, our study additionally correlates relative representations of immune subpopulations to testosterone levels. Thus, higher testosterone levels in Sample 1 are correlated to polarized (Th1, Th17, Th1-17, Th2) and differentiated (effector memory CD4
+, central memory CD4
+, CD8
+ TEMRA) T cell subpopulations. In Sample 2, testosterone levels correlate to a similar range of subpopulations, along with plasmablasts and mature NK cells (CD16
+dimCD16
+). These temporal switches in the differentiation profiles of distinct immune subpopulations may suggest that in patients with lethal outcomes, there may be a defective differentiation of T helper cells [
56] and monocytes. A second possible explanation of the apparent depletion of circulating differentiated and polarized cells may be an enhanced clearance or migration from circulation to peripheral tissues [
57]. Finally, specific subpopulations may become exhausted in late stages of the disease [
58‐
60]. These three putative mechanisms are not mutually exclusive and may take place either simultaneously or dynamically at different time points along the clinical course of the patients. Notably, very recent studies recognize T cell apoptosis and depletion as a feature defining severe COVID-19 [
60].
The observed concordance of lethal outcome in male COVID-19 patients with (i) persistent lymphopenia and neutrophilia, (ii) depletion of circulating differentiated T helper and T cytotoxic cells and non-classical monocytes, (iii) accumulation of undifferentiated immune counterparts, and (iv) failure to reinstate physiological levels of testosterone, mirrored by converse phenotypes in severe survivor patients who have undergone equivalent critical illness and management, makes it appealing to hypothesize a mechanistic relationship bonding these coincident phenotypes. Relevantly, sex hormones have a profound influence on innate and adaptive immune system development, differentiation, and response to challenge [
14,
18] More specifically, androgens have a global anti-inflammatory effect [
26,
61], reflected in higher frequencies of autoimmune diseases in women or in acquired or genetically determined hypogonadism [
21], as compared to men with a normal XY chromosome complement. On the other hand, testosterone replacement therapy in hypogonadal men attenuates inflammation [
62] and androgens suppress thymic precursor development [
63] and promote the terminal differentiation of T cell subpopulations [
64] and monocyte precursors [
65]. Conversely, androgen deprivation through surgical or pharmacological castration in animal models prompts the regeneration of the thymus in aged mice, leading to a relative accumulation of undifferentiated T cell populations (RTE and naïve T cells) [
66] and classical monocytes [
67]. A similar effect of androgen deprivation on T cell development and differentiation has been observed in prostate cancer patients, with an expansion of RTE and naive T cells, particularly among CD4
+ cells [
66,
68].